Insider trade

Officer sold ~$281K of REGN shares in the open market

Traded Nov 7, 2025 · Filed Nov 10, 2025

~$281K
Reported value · 431 sh @ $651.43: 4,233
Holds after · shares reported: +10.5%
stock since the trade · S&P 500 +15.5%, $657.53 → $726.47 on Oct 5

Why it stands out

Regeneron Pharmaceuticals's VP Controller sold $281K of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 7, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 10, 2025

Officer$100K–$500K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$280,766

Shares × reported transaction price

Timing vs results

10 days after results of Oct 28, 2025, 66 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $657.53 on Nov 7, 2025, 36% above its 52-week low and 21% below its high, after a 17% rise over the previous 30 trading days

52-week range $483.07 (Jun 5, 2025) to $828.42 (Nov 8, 2024), 51% of the way up, from 250 adjusted closes. 30 trading days earlier: $563.90 on Sep 26, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Libtayo on Oct 29, 2025, 9 days before this trade.

New use approved (efficacy supplement). Active ingredient: Cemiplimab-Rwlc. From openFDA. Dates only; no link between the two is implied